Information regarding CEO of Cline Scientific AB

Cline Scientific AB's CEO and board member Patrik Sundh has been informed that he has been served with suspicion of market manipulation and is subject to a preliminary investigation. The suspicions relate to the purchase of B shares in Cline to a value of approximately SEK 62,000, which was carried out during November 2022.

The board will not take any measures at the moment, but is awaiting the results of the preliminary investigation and continues to have full confidence in the CEO.

Until the preliminary investigation is completed or closed, no further information will be provided in this matter.

"What happened is regrettable and surprising because I had no intention of manipulating Cline's share price. The reason I bought shares is that I believe in the company and its future. I have only bought shares, not sold a single share and thus not made money from share trading. Against this background, combined with the fact that my purchases only concern approximately SEK 62,000, it is my hope that the preliminary investigation will be closed." CEO Patrik Sundh.

For more information, please contact:
Johan Bjurquist, Chairman of the Board
Phone: +46 (0)73-747 1990

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.